NEWS AND RESOURCES
SF001, a Novel Micellar Polyene, Demonstrates a Prolonged Post-antifungal Effect In vitro against Yeast.
Hufnagel D, et al. Presented at ECCMID. April 27-30, 2024; Barcelona, Spain.
Inoculum Density has an Impact on SF001 Fungicidal Activity against Candida albicans.
Hufnagel D, et al. Presented at ECCMID. April 27-30, 2024; Barcelona, Spain.
Front-Loaded Exposures Increase the Fungicidal Effect of SF001: A Basis for Infrequent Dosing Regimens.
VanScoy BD, et al. Presented at ECCMID. April 27-30, 2024; Barcelona, Spain.
Efficacy assessment of SF001, a next-generation polyene antifungal, in the immunosuppressed mouse model of invasive pulmonary aspergillosis and mucormycosis.
Gebremariam T, et al. Presented at the 11th Advances Against Aspergillosis & Mucormycosis (AAAM) conference. January 20-23, 2024; Milan, Italy.
SF001: a next-generation, long acting, polyene antifungal with reduced nephrotoxicity.
Marr K. Presented at AAAM. January 20-23, 2024; Milan, Italy.
Tuning sterol extraction kinetics yields a renal sparing polyene antifungal.
Maji, A., Soutar, C.P., Zhang, J. et al. Nature 623, 1079-1085 [2023]. https://doi.org/10.1038/s41586-023-06710-4.
Efficacy assessment of SF001, a third-generation polyene antifungal, in the immunosuppressed mouse model of invasive pulmonary aspergillosis.
Gebremariam T, et al. Presented at the 11th Trends in Medical Mycology (TIMM) conference. October 20-23, 2023; Athens, Greece.
A 3rd generation renal sparing polyene antifungal.
Burke MD. Presented at the Mycoses Study Group Education and Research Consortium (MSGERC) Clinical Mycology Today conference. September 7-9, 2022; Albuquerque, NM.
An evaluation of SF001 pharmacokinetics-pharmacodynamics using a neutropenic mouse disseminated candidiasis model.
VanScoy BD et al. Presented at MSGERC. September 7-9, 2022; Albuquerque, NM.
Comparative in vivo activity of SF001 in neutropenic models of invasive fungal infection.
Andes DR et al. Presented at MSGERC. September 7-9, 2022; Albuquerque, NM.
Development of resistance to SF001, a next generation polyene antifungal.
Pillar C et al. Presented at MSGERC. September 7-9, 2022; Albuquerque, NM.
Efficacy assessment of SF001, a next generation polyene antifungal, in the neutropenic mouse model of pulmonary mucormycosis.
Gebremariam T et al. Presented at MSGERC. September 7-9, 2022; Albuquerque, NM.
In vitro activity of SF001, a next generation polyene antifungal, against yeasts and moulds.
Pillar C et al. Presented at MSGERC. September 7-9, 2022; Albuquerque, NM.
Selective tuning of sterol extraction kinetics yields renal sparing antifungal.
Maji A et al. Presented at MSGERC. September 7-9, 2022; Albuquerque, NM.
Structural understanding of renal sparing amphotericin B derivatives.
Soutar C et al. Presented at MSGERC. September 7-9, 2022; Albuquerque, NM.
The next generation polyene SF001 demonstrates broad-spectrum antifungal activity against yeasts, moulds, and endemic fungi.
Wiederhold NP et al. Presented at MSGERC. September 7-9, 2022; Albuquerque, NM.
